Login to Your Account

Celladon, Xencor Try for IPOs; Phase II Drugs Moving Ahead

By Randy Osborne
Staff Writer

Friday, October 11, 2013
While pundits argue over whether the lately upbeat mood for initial public offerings (IPOs) represents a “bubble” or a “boom,” another two biotech firms took the opportunity to file for their chances at the mild frenzy this year.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription